Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Tibet Weixinkang Medicine Co., Ltd. specializes in the production of traditional Tibetan medicine, leveraging unique herbal formulations that are difficult to replicate. The company primarily operates in China, with a focus on expanding its market share in the growing herbal medicine sector, which is driven by increasing consumer interest in natural remedies.
The company generates revenue through the sale of proprietary herbal formulations and supplements, capitalizing on the growing trend towards natural and holistic health solutions. Its competitive advantages include unique access to rare Tibetan herbs and established relationships with local suppliers, which enhance its pricing power.
Regulatory changes affecting herbal medicine approvals in China
Consumer trends towards natural and organic products
Export growth to international markets, particularly in Asia
Partnerships or collaborations with healthcare providers
Regulatory changes that could limit the sale of herbal products
Increased competition from both domestic and international herbal medicine producers
Emergence of new entrants in the herbal market with innovative products
Market share loss to larger pharmaceutical companies entering the herbal space
Limited liquidity due to declining revenue and cash flow generation
Potential reliance on cash reserves for operational stability
moderate - The demand for herbal medicines is somewhat resilient during economic downturns, but overall consumer spending trends can impact sales.
Low - The company has no debt, so rising interest rates do not affect financing costs. However, they could impact consumer spending.
minimal - The company operates with a debt/equity ratio of 0.00, indicating no reliance on credit.
value - Investors may be attracted to the company's low debt levels and potential for recovery in revenue growth.
moderate - The stock has shown significant price fluctuations, with a 1-year return of -23.1%.
